Efficacy and Safety of Poly‐ l ‐Lactic Acid for Correction of Midfacial Volume Loss and Contour Defects: A Prospective, Multicenter, Randomized, Parallel‐Controlled, Evaluator‐Blinded, Superiority Trial
Journal of Cosmetic Dermatology · 2025-07 · 24 (7)
DOI: 10.1111/jocd.70230 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Cosmetic Dermatology, online erschienen am 18.07.2025. Verfasst von Yi Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plastic Surgery, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences…. Hauptthemen laut MEDLINE: Polyesters, Dermal Fillers, Cosmetic Techniques. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Municipal Natural Science Foundation, Natural Science Foundation of Beijing Municipality.
Abstract (Originalsprache)
Background
Poly‐ l ‐lactic acid (PLLA) is widely used in esthetic medicine due to its excellent biocompatibility and biodegradability. This study aimed to evaluate the effectiveness and safety of PLLA facial filler in correcting midfacial volume loss and/or contour defects.
Methods
In this prospective, multicenter, randomized, assessor‐blinded, superiority clinical trial, 331 subjects were randomly assigned to receive either PLLA (experimental group) or hyaluronic acid (HA, control group). Efficacy was assessed using the Midfacial Volume Scale (MMVS) and Global Aesthetic Improvement Scale (GAIS). Safety was evaluated based on adverse events.
Results
The PLLA group demonstrated significantly higher efficacy in MMVS scores compared to the HA group (90.57% vs. 51.01%, difference of 39.56%, 95% CI: 30.34%–48.78%). These results were consistent across worst‐case and per‐protocol analyses. Secondary outcomes revealed higher MMVS and GAIS scores in the PLLA group at 6 months (MMVS: 93.04% vs. 69.33%, GAIS investigator rating: 99.37% vs. 86.67%) and 12 months (MMVS: 84.91% vs. 46.98%, GAIS investigator rating: 94.34% vs. 74.50%) ( p < 0.05). Participant satisfaction surveys showed higher satisfaction in the PLLA group ( p < 0.05). Safety analysis revealed no significant differences in vital signs, laboratory tests, or adverse events ( p > 0.05), with a slightly higher incidence of injection site reactions in the PLLA group, which resolved within 1–3 days.
Conclusion
The comprehensive analysis of results indicates that PLLA is a safe and effective treatment for the correction of midfacial volume loss and midfacial contour defects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Plastic Surgery, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
ORCID-Profile: Yi Zhang
Förderung
- Beijing Municipal Natural Science Foundation
- Natural Science Foundation of Beijing Municipality
Zitieren
APA
Zhang, Y., Zhang, X., Gao, X., Wei, Y., Qian, W., Sun, Z., Ding, J., Bao, S., Ren, R., & Zhao, H. (2025). Efficacy and Safety of Poly‐ l ‐Lactic Acid for Correction of Midfacial Volume Loss and Contour Defects: A Prospective, Multicenter, Randomized, Parallel‐Controlled, Evaluator‐Blinded, Superiority Trial. Journal of Cosmetic Dermatology, 24(7). https://doi.org/10.1111/jocd.70230
Vancouver
Zhang Y, Zhang X, Gao X, Wei Y, Qian W, Sun Z, et al. Efficacy and Safety of Poly‐ l ‐Lactic Acid for Correction of Midfacial Volume Loss and Contour Defects: A Prospective, Multicenter, Randomized, Parallel‐Controlled, Evaluator‐Blinded, Superiority Trial. Journal of Cosmetic Dermatology. 2025;24(7). doi:10.1111/jocd.70230
BibTeX
@article{Zhang2025,
author = {Zhang, Yi and Zhang, Xinling and Gao, Xuejie and Wei, Yaqi and Qian, Wenjiang and Sun, Zhongyang and Ding, Jinping and Bao, Shiwei and Ren, Rongxin and Zhao, Hongyi},
title = {Efficacy and Safety of Poly‐ l ‐Lactic Acid for Correction of Midfacial Volume Loss and Contour Defects: A Prospective, Multicenter, Randomized, Parallel‐Controlled, Evaluator‐Blinded, Superiority Trial},
journal = {Journal of Cosmetic Dermatology},
year = {2025},
volume = {24},
number = {7},
doi = {10.1111/jocd.70230}
}
EUVIMED